Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...

Earlier in 2019 Sanofi also paid Regeneron $462 million to exit from an immuno-oncology alliance formed in 2015, and in 2017 said they would end discovery research in new antibody drugs.

Sanofi and Regeneron have just halted a 466-patient phase 3 trial of the drug in combination with chemo rarely, saying they saw a significant improvement in overall survival versus chemo alone in ...

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...

On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), ...

"Regeneron had a strong third quarter marked ... is expected to announce a final decision in the coming months. The Company and Sanofi announced that a confirmatory Phase 3 trial met the primary ...

Hence, investors should also focus on Dupixent’s performance, sales of which are recorded by Sanofi SNY. Regeneron has a collaboration agreement with Sanofi for drugs like Dupixent and Kevzara.

Within the Sanofi antibody collaboration, LDL cholesterol reduction drug Praluent has seen a slow launch trajectory because of payer restrictions, but we think US sales growth can rebound now that ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) will present data from the Phase 3 LIBERTY-CUPID Study C evaluating the investigational use ...

On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), ...

Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023Third quarter 2024 Dupixent® global net sales(recorded by ...

Sales of Dupixent, Sanofi’s blockbuster eczema drug, rose 23.8% to 3.48 billion euros. Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease New pharma ...